Protagonist Therapeutics Inc.
Develops injectable and oral peptide therapeutics for hematologic and inflammatory diseases, led by Rusfertide (phase 3 polycythemia vera) and Icotrokinra (phase 3 oral anti‑inflammation). The pipeline also targets ulcerative colitis with PN‑943 and metabolic disease with PN‑88.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical Practices
- Employees: 128
- HQ: Newark
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.